Antibody-drug conjugates

Antibody-drug conjugates (ADCs) represent a promising class of anti-cancer therapeutics with significant therapeutic potential.

This innovative approach combines the targeting specificity of mAbs with the potent cytotoxicity of chemotherapeutic agents, offering improved efficacy and reduced systemic side effects compared to conventional chemotherapy.

Mabqi’s LiteMab Antibody Discovery Studio is well suited to support ADC discovery campaigns.

The company benefits from a strong track record through partnered programs and discovery campaigns:

Fully human antibody display libraries to generate native antibodies or pH-sensitive antibodies
AI-powered Dual technology platform (Phage-yeast display): selection process optimized for rapid identification of best clones
Hits screening: hits characterization and screening. If initially requested, of pH-sensitive characteristic is confirmed (in vitro binding and kinetics)
Hits validation: functional assays such as internalization assays, epitope binning, in vitro cytotoxicity on target expressing cells, other assays on-demand.

Mabqi achieves first out-licensing ADC milestone.

The company announced in 2026 the exercise of an option under its research collaboration agreement for a jointly discovered antibody-drug conjugate (ADC), subsequently acquired by a leading pharmaceutical company.

This transaction underscores the strategic value of LiteMab Antibody Discovery platform in advancing oncology therapeutics.

Full press release available here.

Feel free to reach out to learn more on our expertise for ADC programs.